TrialJCO precision oncology2021

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.

Mads H Haugen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.